Caffeine; ergotamine tartrate - Generic Drug Details

What are the generic drug sources for caffeine; ergotamine tartrate and what is the scope of freedom to operate?

Caffeine; ergotamine tartrate is the generic ingredient in four branded drugs marketed by Novartis, Cosette, Chartwell Rx, Anda Repository, Hikma Intl Pharms, and Organon Usa Inc, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for caffeine; ergotamine tartrate

US Patents:	0
Tradenames:	4
Applicants:	6
NDAs:	7
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	caffeine; ergotamine tartrate at DailyMed

Pharmacology for caffeine; ergotamine tartrate

Drug Class	Central Nervous System Stimulant Ergotamine Derivative Methylxanthine
Physiological Effect	Central Nervous System Stimulation

Anatomical Therapeutic Chemical (ATC) Classes for caffeine; ergotamine tartrate

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

N02CA	Ergot alkaloids
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

N06BC	Xanthine derivatives
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for caffeine; ergotamine tartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	CAFERGOT	caffeine; ergotamine tartrate	SUPPOSITORY;RECTAL	009000-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	CAFERGOT	caffeine; ergotamine tartrate	TABLET;ORAL	006620-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hikma Intl Pharms	ERGOTAMINE TARTRATE AND CAFFEINE	caffeine; ergotamine tartrate	TABLET;ORAL	040510-001	Sep 17, 2004		DISCN	No	No
Anda Repository	ERGOTAMINE TARTRATE AND CAFFEINE	caffeine; ergotamine tartrate	TABLET;ORAL	040590-001	Sep 16, 2005		RX	No	Yes

Market Dynamics and Financial Trajectory for Caffeine and Ergotamine Tartrate

Last updated: February 14, 2026

Overview

The combined market for caffeine and ergotamine tartrate involves products used primarily for neurological and stimulant purposes. Caffeine is a widely consumed stimulant, present in beverages and OTC medications. Ergotamine tartrate is a prescription drug mainly used to treat migraines but has seen declining use due to safety concerns and alternative therapies.

---

Market Size and Growth Trends

• Caffeine Market: Estimated at USD 13.5 billion in 2022, projected to reach USD 17.7 billion by 2028; CAGR of approximately 4.4% (source: Grand View Research).[1]
• Ergotamine Tartrate Market: Estimated at USD 40-50 million in 2022, with minimal growth projections; declining due to safety profiles and availability of newer treatments.[2]

Key Drivers

• Caffeine: Increased consumption in energy drinks, dietary supplements, and OTC medications; rising awareness of cognitive enhancement.
• Ergotamine Tartrate: Decline due to adverse effects, such as vasoconstriction and potential for Ergotism; replaced by triptans and other migraine therapies.

---

Patent and Regulatory Landscape

• Caffeine:
  • Widely available; no recent patent restrictions.
  • Regulatory agencies such as the FDA recognize caffeine as safe in moderate amounts but restrict high-dose formulations.
• Ergotamine Tartrate:
  • Patent protection expired decades ago.
  • Regulatory limits imposed on formulations; recent approval for combination products has been limited.

Patent Holders and Competitive Dynamics

• Major global pharmaceutical companies, including Johnson & Johnson and Teva, Market caffeine formulations.
• Ergotamine-related products mainly supplied by generic manufacturers; limited R&D investment due to concerns over safety profiles.

---

Pricing and Reimbursement

• Caffeine:
  • OTC status permits competitive pricing.
  • Retail price varies by formulation and concentration; no significant reimbursement policies.
• Ergotamine Tartrate:
  • Typically prescription-based; reimbursement depends on healthcare system policies.
  • Price has remained stable due to generic manufacturing.

---

Supply Chain and Manufacturing

• Caffeine:
  • Sourced primarily from coffee, tea, and synthetic manufacturing.
  • Large-scale synthesis is well-established with low production costs.
• Ergotamine Tartrate:
  • Derived from naturally occurring ergot alkaloids.
  • Production limited by strict quality controls and regulatory oversight, raising manufacturing complexity.

---

Competitive Landscape

• Caffeine:
  • Fragmented market with competition from beverage producers, supplement companies, and OTC drug manufacturers.
  • Innovations include sustained-release formulations and potency variants.
• Ergotamine Tartrate:
  • Dominated by a handful of generic manufacturers.
  • Few new R&D efforts due to safety concerns and patent expirations.

---

Financial Outlook

• Caffeine:
  • Revenue growth driven by increasing demand for energy products.
  • Interest in functional foods and beverages sustaining the market.
  • Market players investing in novel delivery mechanisms and formulations.
• Ergotamine Tartrate:
  • Revenue stable but declining.
  • Limited expectations for growth; focus shifts toward newer, safer migraine therapies.

---

Regulatory and Market Challenges

• Regulatory scrutiny on stimulant content and safety concerns.
• Substitution of ergotamine with triptans and other migraine-specific drugs reduces demand.
• Market entry barriers for new caffeine formulations include regulatory approval and consumer acceptance.

---

Potential Future Trends

• Caffeine: Expansion into new formats, such as transdermal patches and ingestible tablets. Growth in niche markets like cognitive enhancers.
• Ergotamine Tartrate: Likely phased out further; ongoing safety issues limit new formulations.

---

Key Takeaways

• The caffeine market exhibits steady growth driven by increasing consumption and product innovation.
• The ergotamine tartrate market shrinks or remains stagnant, largely replaced by safer, more effective migraine medications.
• Most revenue for caffeine is generated from OTC sales, with low production costs due to established supply chains.
• Ergotamine derives revenue mainly from legacy formulations; patent expiration and safety issues hinder innovation.
• Regulatory landscapes shape market trajectories significantly for both substances, influencing commercialization strategies.

---

FAQs

1. What is the primary driver behind caffeine market growth?
Increasing consumption in energy drinks, dietary supplements, and OTC products fuels demand.

2. Why is the ergotamine tartrate market declining?
Safety concerns, particularly vasoconstrictive side effects, lead to replacement by newer migraine medications like triptans.

3. Are there any recent innovations in caffeine formulations?
Yes, sustained-release formulations and transdermal patches are under development to improve absorption and efficacy.

4. How do regulatory policies affect ergotamine tartrate sales?
Stringent safety regulations and expiration of patents limit new product development and market expansion.

5. What are the main challenges for companies entering the caffeine market?
Market saturation, regulatory approval processes for novel formulations, and consumer preferences for established products.

---

Citations

1. Grand View Research. "Caffeine Market Size, Share & Trends Analysis." 2022.
2. MarketWatch. "Ergotamine Tartrate Market Analysis." 2022.